



HAL
open science

Non-cell autonomous OTX2 transcription factor regulates anxiety-related behavior in the mouse

Clémentine Vincent, Javier Gilabert-Juan, Rachel Gibel-Russo, Daniel Alvarez-Fischer, M.-O Krebs, Gwenaëlle Le Pen, Alain Prochiantz, Ariel A Di Nardo

► **To cite this version:**

Clémentine Vincent, Javier Gilabert-Juan, Rachel Gibel-Russo, Daniel Alvarez-Fischer, M.-O Krebs, et al.. Non-cell autonomous OTX2 transcription factor regulates anxiety-related behavior in the mouse. *Molecular Psychiatry*, 2021, 10.1038/s41380-021-01132-y . inserm-03229514

HAL Id: inserm-03229514

<https://inserm.hal.science/inserm-03229514>

Submitted on 19 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Non-cell autonomous OTX2 transcription factor regulates anxiety-related behavior in the mouse

C. Vincent^{1*}, J. Gilabert-Juan^{1‡*}, R. Gibel-Russo¹, D. Alvarez-Fischer^{2,3}, M.-O. Krebs^{4,5,6}, G. Le Pen⁴, A. Prochiantz^{1†} & A.A. Di Nardo^{1†}

¹Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS UMR 7241, INSERM U1050, Labex MemoLife, PSL Research University, Paris, France.

²Institute of Neurogenetics, University of Lübeck, Lübeck, Germany

³Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany

⁴INSERM, Laboratoire de Physiopathologie des maladies Psychiatriques, UMR S1266 Institut de Psychiatrie et Neurosciences de Paris, Université Paris Descartes, Paris, France.

⁵Institut de Psychiatrie, CNRS GDR 3557, Paris, France.

⁶Faculté de Médecine Paris Descartes, Service Hospitalo Universitaire, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Paris, France.

*C.V. and J.G.-J. contributed equally to this work.

‡Present address: Department of Anatomy, Histology and Neuroscience, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.

†Corresponding authors: ariel.dinardo@college-de-france.fr, alain.prochiantz@college-de-france.fr

Running title

Cerebrospinal fluid OTX2 regulates anxiety

ABSTRACT

The OTX2 homeoprotein transcription factor is expressed in the dopaminergic neurons of the ventral tegmental area, which projects to limbic structures controlling complex behaviors. OTX2 is also produced in choroid plexus epithelium, from which it is secreted into cerebrospinal fluid and transferred to limbic structure parvalbumin interneurons. Previously, adult male mice subjected to early-life stress were found susceptible to anxiety-like behaviors, with accompanying OTX2 expression changes in ventral tegmental area or choroid plexus. Here, we investigated the consequences of reduced OTX2 levels in *Otx2* heterozygote mice, as well as in *Otx2*^{+AA} and *scFvOtx2*^{tg/0} mouse models for decreasing OTX2 transfer from choroid plexus to parvalbumin interneurons. Both male and female adult mice show anxiolysis-like phenotypes in all three models. In *Otx2* heterozygote mice, we observed no changes in dopaminergic neuron numbers and morphology in ventral tegmental area, nor in their metabolic output and projections to target structures. However, we found reduced expression of parvalbumin in medial prefrontal cortex, which could be rescued in part by adult overexpression of *Otx2* specifically in choroid plexus, resulting in increased anxiety-like behavior. Taken together, OTX2 synthesis by the choroid plexus followed by its secretion into the cerebrospinal fluid is an important regulator of anxiety phenotypes in the mouse.

Keywords

Choroid plexus, cerebrospinal fluid, stress, homeobox, limbic systems

INTRODUCTION

The vertebrate *orthodenticle* orthologue *Otx2* homeoprotein acts as a gap gene in early development for the anterior part of the central nervous system, including the telencephalon [1, 2]. However, *Otx2* expression is rapidly turned off and has already ceased in the mouse cerebral cortex parenchyma at embryonic day 15 (E15). In contrast, its expression persists throughout life in the pineal gland, choroid plexus (ChP), and in neurons within the septum, thalamus, cerebellum and midbrain, including the mesencephalic dopaminergic (mDA) neurons of the ventral tegmental area (VTA) [3]. These neurons innervate several cerebral structures regulating complex behaviors [4, 5] and require *Otx2* expression for their proper development and survival [6, 7], suggesting implication in psychiatric disorders.

Roles for *Otx2* in juvenile and adult control of complex traits such as depression or anxiety have been recently revealed in maltreated children and in mouse models of early-life stress [8–10]. Periodic separation of mouse pups from their mothers, during a critical period from postnatal day 10 (P10) to P20, results in a transient decrease in *Otx2* expression in the VTA that leads directly to latent anxiety and depressive phenotypes in male adults [9]. In a separate study of anxiety induced by maternal separation and early weaning, it was proposed that *Otx2* upregulation in the ChP and increased OTX2 levels in the ventral hippocampus inhibitory interneurons may participate in the anxiety phenotype [10]. While the first study implicates cell-autonomous activities for OTX2, this second study suggests non-cell-autonomous functions.

We have shown that OTX2 is secreted by ChP into the cerebrospinal fluid (CSF) and transported to the brain parenchyma where it is primarily captured by the fast-spiking GABAergic interneurons that express parvalbumin (PV), hereafter referred to as PV cells [11]. Indeed, several homeoproteins have been shown to transfer between cells in both embryonic and postnatal contexts [12, 13], as the sequences responsible for their internalization and secretion are highly conserved [14, 15]. OTX2 also contains a glycosaminoglycan-binding motif, similar to other homeoproteins [3], which mediates specific capture by cortical PV cells through interaction with proteoglycan-rich perineuronal nets (PNNs) that enwrap these cells [16, 17]. During mouse postnatal development, the privileged accumulation of OTX2 within PV cells has been shown to regulate critical periods of plasticity in the primary visual cortex, primary auditory cortex and medial prefrontal cortex (mPFC) [18, 19]. Furthermore, pharmacological or genetically-induced decrease of OTX2 content in PV cells of the adult cortex reopens a window of plasticity, allowing for the recovery of binocular vision in a mouse model of amblyopia [11, 16].

It has been hypothesized that critical periods impact the development of mood disorders such as anxiety and schizophrenia [20–22]. Supporting the above-mentioned maternal separation results, we recently found that the *Otx2*^{+AA} mice display prolonged acquisition of acoustic preference in adulthood linked to anxiolysis [19]. This constitutive mouse model shows reduced OTX2 affinity for PNNs, which results in decreased accumulation of OTX2 in PV cells and delayed critical period timing across modalities, suggesting that this transfer may regulate complex animal behaviors. However, it is not clear whether this regulation is due to purely non-cell-autonomous CSF-borne OTX2 activity or includes some contribution by cell-autonomous OTX2 function in ChP, VTA or other brain region. To begin addressing this important question, we aimed to better characterize the constitutive *Otx2* heterozygote (*Otx2-het*) mouse line [23, 24]. By using a battery of behavioral tests, we find these mice display anxiolysis-like behavior with no changes in motor activities, cognition, depression-like behavior or sensorimotor gating. This phenotype is recapitulated in mouse models of non-cell-autonomous OTX2 loss-of-function and can be rescued by *Otx2* overexpression in the ChP. This ChP-specific expression also rescued PV cell staining in the mPFC, and positions ChP OTX2 as a regulator of anxiety phenotypes.

MATERIAL AND METHODS

Ethics statement

All animal housing and experimental procedures were carried out in accordance with the recommendations of the European Economic Community (2010/63/UE) and the French National Committee (2013/118). For surgical procedures, animals were anesthetized with Xylazine (Rompun 2%, 5 mg/kg) and Ketamine (Imalgene 500, 80 mg/kg) by intraperitoneal injection. This research (project no. 00704.02) was approved by Ethics committee n° 59 of the French Ministry for Research and Higher Education.

Mice

The *Otx2-het* mouse line was generated in the laboratory of Antonio Simeone (CEINGE, Naples), with the *Otx2* coding sequence and introns replaced by *GFP* [23]. *Otx2*^{+GFP} males were crossed with B6D2F1 females to obtain *Otx2-het* mice. The *Otx2*^{+AA} mouse line was generated through a knock-in approach, as described previously [24]. The conditional secreted single-chain antibody (scFv) OTX2 *scFvOtx2*^{tg/0} mouse line was generated by targeted transgenics in the *Rosa26* locus, as described previously [25]. Mice were raised in a 12-hour light/dark cycle with 2 to 5 (male) or 6 (female) animals per cages. Temperature was

controlled ($21\pm 2^\circ\text{C}$), and food and water provided ad libitum.

Stereotaxic injections

Adeno-associated viruses (AAV) were generated by Vector Biolabs: AAV5(CMV)HAOtx2-2A-mCherry and AAV5(CMV)mCherry. Bilateral intracerebroventricular (icv) stereotaxic injections (bregma: $x = -0.58$ mm, $y = \pm 1.28$ mm, $z = 2$ mm) of 2 μl high-titer AAV ($\sim 10^{12}$ GU/ml) were performed with a Hamilton syringe at a rate of 0.3 $\mu\text{l}/\text{min}$. Mice injected between 2 and 3 months of age, and were used for biochemical, histological and behavioral analysis at least 3 weeks after infection. Cre-TAT icv injections were performed in *scFvOtx2^{tg/0}* mice as previously described [11]. Behavior was tested 4 weeks after injection.

Behavior analyses

Tests were performed from P90 to P120 in littermate groups of female or male separately in the following order: locomotor activity, Y-maze, elevated plus maze, light-dark box, rotarod, tail-suspension, prepulse inhibition, forced swimming test. Except for rotarod, tail-suspension and prepulse inhibition tests, behavior was registered using a semi-automated infrared system (Viewpoint, Lyon). All tests were done during the light cycle between 9:00 and 18:00. Animals were habituated to the testing room for at least 30 min and the experimenter was blind to animal genotype or treatment. To eliminate odor cues, each apparatus was thoroughly cleaned after each animal.

Y maze. Short-term spatial memory and locomotor activity was evaluated by spontaneous alternative exploration of the Y-maze during 10 min. The maze consisted of 3 alleys diverging at 120° from one another, 40 cm long, 15 cm width, with black 30 cm high Perspex borders decorated differently in each arm, which were illuminated at 50 lux. The mouse was placed at the tip of one arm and the time spent visiting each of the other arms sequentially was counted as a memory performance.

Elevated plus maze. A cross-shape maze elevated at 70 cm from the floor was illuminated at 50 lux. Two “closed” arms facing each other and protected by black Perspex walls (20 cm high), are crossed perpendicularly by the two “opened” unprotected arms. The mouse was placed at the center of the cross and activity was recorded for 10 min. Total distance traveled, the time spent in the open arms and the number of entries into each arm were measured.

Light-dark box. Boxes are composed of a dark (black walls, floor and roof) and light (white walls and floor, no roof, 150 lux) compartments of equal volume (20 x 20 x 30 cm)

linked by a small opening. The mouse is placed in the light box facing the opening, and anxiety is measured by the time spent in the light compartment over a 10 min period.

Rotarod. Equilibrium and motor coordination were measured in a progressively accelerating (from 2 to 40 rpm during 5 min) rotarod (model 47600, Ugo Basile, Italy). Three daily trials separated by 90 min intervals were performed during 2 days.

Tail-suspension test. Mice were suspended by the tail with adhesive linked to a gauge detecting movement (automated system BIOSEB, France), during 6 min. Immobility was interpreted as a sign of depression-like behavior.

Forced swimming test. Behavior was also evaluated by registering the length of freezing periods of mice placed in a see-through Perspex cylinder (h, 25 cm; d, 13 cm) full of water (h, 20 cm; 25 °C). On the first day, mice were habituated during 10 min; mice were tested on the second day during a period of 6 min. An infrared panel positioned vertically behind the cylinder detects mice movements. Immobility was interpreted as a sign of depression-like behavior.

Prepulse Inhibition test. Testing was carried out in a SR-Lab system (San Diego Instruments, USA). Each mouse was placed in a startle chamber, and acoustic noise bursts were presented via a speaker mounted 26 cm above. Throughout the session, a background noise level of 68 dB was maintained. After a 5-min acclimatization period (68 dB background noise), 10 startle pulses (120 dB, 40 ms duration) were presented with an average inter-trial interval of 15 s. During the next 20 min, no stimulus (background noise, 68 dB), prepulses alone (72, 76, 80 or 84 dB, 20 ms duration), startle pulses alone, and prepulses followed 80 ms later by startle pulses were presented 10 times, randomly distributed. Percent prepulse inhibition (PPI) was calculated as $[100 - 100 \times (\text{startle response of acoustic startle from acoustic prepulse and startle stimulus trials}) / (\text{startle response alone trials})]$.

Dosage of amines and amine metabolites

Brains were dissected in ice-cold PBS and dry tissue was kept at -80°C. Extracts were prepared and analyzed by HPLC using a reverse phase column (Nucleosil 120-3 C18; Knauer) with electrochemical detection as described [26]. Data were recorded and quantified using HPLC Chromeleon computer system (Dionex).

Quantitative RT-PCR

Mice were sacrificed by cervical dislocation, and mPFC, amygdala, hippocampus and/or ChP were microdissected in ice-cold PBS and frozen in liquid nitrogen. Total RNA was extracted

with the AllPrep DNA/RNA Mini Kit (Qiagen 80204), with on-column genomic DNA digestion, and evaluated by spectroscopy (Nanodrop, Palaiseau, France). cDNA was synthesized from 500 ng of total RNA with QuantiTect Reverse Transcription kit (Qiagen 205313). Quantitative PCR reactions were carried out in triplicate with SYBR Green I Master Mix (Roche S-7563) on a LightCycler 480 system (Roche). Expression was calculated by using the $2^{-\Delta\Delta Ct}$ method with *Ywhaz* as a housekeeping reference gene. Primer sequences: *PV*, Fwd-AAGAAACAAAGACGCTTCTGGC, Rev-ACTGAACAGAACTCAGGAGGG; *SST*, Fwd-CTGCGACTAGACTGACCCAC, Rev-AAAGCCAGGACGATGCAGAG; *Gadd45b*, Fwd-TCTCTAGAGGAACGCTGAGACC, Rev-GTAGGGTAGCCTTTGAGGGATT; *Arc*, Fwd-AGAGCTGAAGGTGAAGACAAGC, Rev-CAAGAGGACCAAGGGTACAGAC; *Nr4a1*, Fwd-AGGAGACCAAGACCTGTTGCTA, Rev-TGTAGTACCAGGCCTGAGCAGA; *mt-Nd4*, Fwd-AATATACATAATTATTACCACCCAACG, Rev-TGTCAGACCTGTAATTAGTTTTGGA; *Ibal*, Fwd-CTCAGCTCACCCCATTCCTG, Rev-ACATCAGCTTCTGTTGAAATCTCC; *Ywhaz*, Fwd-TTGATCCCAATGCTTCGC, Rev-CAGCAACCTCGGCCAAGT.

Immunohistochemistry

Anesthetized mice were perfused transcardially (10 ml/min) with 20 ml of PBS and 30 ml of 4% paraformaldehyde in PBS. Dissected brains were post-fixed in 4% paraformaldehyde at 4 °C for 1 h, rinsed in PBS, soaked in 20% sucrose-PBS at 4°C for 12-24 h and frozen. Fluorescent immunohistochemistry was performed on cryostat sections (20 µm). Briefly, after permeabilization with 1% Triton for 20 min, sections were incubated in 100 mM glycine for 20 min, blocked with PBS, 0.2% Triton, 10% normal goat serum (NGS) for 45 min and incubated overnight with primary antibodies: anti-tyrosine hydroxylase antibody (rabbit, abcam, 1/500); anti-dopamine transporter (rat, Millipore, 1/5000); biotinylated *Wisteria floribunda* agglutinin (1/100, Sigma L1516); anti-parvalbumin (rabbit, Swant, 1/500); anti-tryptophan hydroxylase 2 (rabbit, abcam, 1/500); anti-OTX2 (mouse monoclonal, in house) in PBS, 1% Triton, 3% NGS at 4 °C. After 3 washes in PBS, 1% Triton, secondary antibodies were incubated (Alexa Fluor-conjugated, Molecular Probes) for 2 h at room temperature (1/2000). After 3 washes in PBS, 1% Triton, sections were mounted in DAPI-fluoromount medium and kept at 4 °C.

DAB-immunohistochemistry was performed on free-floating cryostat sections (40 µm). Endogenous peroxidase was removed with a 5 min incubation in 0.3% H₂O₂, 0.2% Methanol.

Sections were permeabilized and blocked as above and incubated during 12-24h with an anti-tyrosine hydroxylase antibody (rabbit, Pel Freez Biologicals, 1/1000) in PBS, 0.1% Triton, 3% NGS at 4°C. After 3 washes in PBS, 0.1% Triton, a biotin-coupled anti-rabbit antibody (1/2000) was added for 2h at room temperature. After 3 washes in PBS, 0.1% Triton, biotin was detected by using the Vectastain Elite ABC HRP kit and Peroxidase Substrate kit (1h of ABC buffer + reaction with DAB, Vectorbiolabs), and the slides were washed in water prior to mounting.

Images were acquired with either a Leica SP5 or SP8 confocal microscope. For VTA cell counting, every second section (containing VTA) was counted by stereology using Stereo Investigator software (MBF Bioscience Inc.) at a 40X magnification. Amygdala were imaged at 20X and the density of fiber staining was assessed by the mean grey value option with ImageJ software. The infralimbic mPFC were imaged at 20X and 40X and cell number and staining intensity was measured with ImageJ and in-house macros.

Statistical Analysis

All statistics were performed using Prism (version 8.1.2, GraphPad Software). In order to avoid type II errors, outliers were defined as more than 2 standard deviations from the group mean and were removed from analysis. Main effects and interactions with more than 2 groups were determined using analyses of variance (ANOVA) or 2-way ANOVA with Tukey's multiple comparison *post hoc* test. The *t*-test was used for single comparisons among two groups.

RESULTS

***Otx2-het* mice show only anxiolysis-like behaviors**

Three-month-old *Otx2-het* and wild-type (WT) littermates were analyzed for motor coordination (rotarod), depression-like behavior (tail-suspension and forced swimming tests), cognition (Y-maze), sensorimotor gating (prepulse inhibition) and anxiety (light-dark box and elevated plus maze). Motor coordination measured by the rotarod test showed differences between males and females ($F(3, 270) = 28.50$; $p < 0.0001$), but not between WT and *Otx2-het* animals (Supplementary Fig. 1a). Depression-like behavior measured by the forced swimming (Supplementary Fig. 1b) and tail suspension (Supplementary Fig. 1c) tests showed no differences between the two genotypes, with a difference between males and females in the tail suspension test only for which females showed less effort to escape (77.09 ± 12.84 vs 39.09 ± 5.41 ; $F(1, 52) = 10.40$; $p = 0.0022$). The short-term spatial memory test (Y maze)

was used to measure both locomotor activity and memory. Although females show higher motor activity (4944 ± 130 (males) vs 4439 ± 160 ; $F(1, 54) = 4.75$; $p = 0.0337$), here again no differences were found between the two genotypes (Supplementary Fig. 1d). Another absence of difference between genotypes was found in the prepulse inhibition (PPI) test (Supplementary Fig. 1e, f). Together, these results suggest the loss of one *Otx2* allele does not affect motor activities, cognition, depression-like behavior or sensorimotor gating.

In contrast, strong differences between WT and *Otx2-het* mice appeared in the light-dark box (LDB) and the elevated plus maze (EPM) anxiety tests (Fig. 1a, b). *Otx2-het* mice spent more time than WT in the light compartment of the LDB (58.84 ± 9.64 (WT) vs 115.93 ± 13.87 ; $F(1, 57) = 11.34$; $p = 0.0014$) (Fig. 1A) as well as in the open arms of the EPM (6.00 ± 1.44 (WT) vs 46.13 ± 8.71 ; $F(1, 52) = 18.49$; $p < 0.0001$) and with increased percentage of entries in the open arms (6.83 ± 1.29 (WT) vs 16.08 ± 2.27 ; $F(1, 58) = 13.35$; $p = 0.0006$). Furthermore, the increases in the open arms visits and time are in parallel with an increase of the distance travelled by the animals in the EPM ($2.21 \text{ m} \pm 0.11$ (WT) vs $2.68 \text{ cm} \pm 0.16$; $F(1, 56) = 6.05$; $p = 0.017$). These effects are similar in both sexes given the absence of significant sex-genotype effect in each test (Fig. 1). The EPM test was also conducted in absence of light (Fig. 1c) ensuring that the anxiolysis-like behavior associated with the loss of one *Otx2* allele is independent of a putative vision deficit created by decreased *Otx2* expression [24] (6.86 ± 1.78 (WT) vs 25.34 ± 5.67 ; $F(1, 42) = 10.09$; $p = 0.0028$), showing again increased percentage of entries in the open arms in the mutants compared with the WT (6.44 ± 3.15 (WT) vs 14.03 ± 0.47 ; $F(1, 44) = 7.07$; $p = 0.011$) and the total distance travelled by the mutant mice ($2.02 \text{ m} \pm 0.17$ (WT) vs $2.70 \text{ m} \pm 0.26$; $F(1, 43) = 4.74$; $p = 0.035$). The EPM test was thereafter used as an anxiety-like read-out in all experiments.

The low anxiety behavior of *Otx2-het* mice in the EPM test does not reflect a dopaminergic or serotonergic phenotype

In a previous study, it was found that mice heterozygous for *Engrailed-1*, a homeogene expressed in the mDA neurons of the ventral midbrain, experience a progressive loss of these neurons in the substantia nigra (SNpc) and VTA beginning at 6 weeks [27]. This results in a 40% and 20% neuronal loss at 48 weeks in the SNpc and VTA, respectively. *Otx2* is expressed in the adult VTA [7], and the projections of the VTA into several target structures, including the hippocampus, nucleus accumbens, amygdala, and the mPFC, may be involved in anxiety regulation [9]. This led us to analyze the hypoanxiety behavior of *Otx2-het* mice between 1 and 4 months of age, including the age at which behavior was tested (3 months) to

determine whether the behavior was appearing/disappearing with the age (Fig. 1d). We observed no changes in the anxiety level in any of the interrogated time points when time in open arms was evaluated ($F(1, 229) = 56.06$; $p < 0.0001$; 1 mo, $p = 0.03$; 2 mo, $p = 0.0019$; 3 mo, $p = 0.032$; 4 mo, $p < 0.0001$) and percentage of entries in the open arms ($F(1, 248) = 45.45$; $p < 0.0001$; 1 mo, $p = 0.098$; 2 mo, $p = 0.001$; 3 mo, $p = 0.0038$; 4 mo, $p = 0.0028$). For the distance traveled by the animals we only observed differences at 4 months of age ($F(1, 248) = 10.24$; $p = 10.24$; 4 mo, $p = 0.0016$). Thus, anxiolysis-like behavior is established very early and is maintained during this period, making it unlikely that it is due to mDA progressive neuronal loss.

This hypothesis was further confirmed by stereology counting of tyrosine hydroxylase (TH)-positive cell bodies of the VTA (Fig. 2a), which showed no differences between 3-month-old *Otx2-het* mice and their WT littermates. However, as illustrated in a study on SNpc mDA neurons in WT and *Engrailed-1* heterozygotes, cells bodies can be present while axons begin degenerating as characterized by their fragmentation, clearly visible both in the medial forebrain bundle and in the striatum [28]. Hence, we evaluated the state and density of the TH- and dopamine transporter (DAT)-positive fibers in the basolateral amygdala, a region responsible for the fear response and receiving mDA terminals from the VTA [29]. No significant changes were observed neither for the density of any of the two markers of dopaminergic neurotransmission, nor for the morphology of the fibers (Fig. 2b).

To further evaluate a possible dopaminergic phenotype, dopamine (DA) and its main metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured in the cortex (anterior and posterior), the striatum, and the hippocampus of 3-month-old WT and *Otx2-het* mice from the same litter (Fig. 2c). The amounts are very similar in both genotypes and in all studied structures, thus eliminating both a change in absolute DA concentrations and in DA metabolism.

Early *Otx2* hypo-morphism can also lead to an increase in the number serotonin (5HT) neurons by an anterior shift in the midbrain/hindbrain boundary [30, 31]. Because 5HT has been implicated in anxiety regulation [32, 33], we measured the levels of 5HT and of its main metabolite 5HIAA. We found no differences between animals of either genotype and in any of the studied structures (Fig. 2d). Furthermore, the serotonergic fibers in the amygdala marked with the TPH2 antibody showed similar morphology and density in both WT and *Otx2-het* mice (Fig. 2b).

Non-cell-autonomous OTX2 mouse models recapitulate anxiolysis-like behavior

The absence of VTA-dependent changes led us to consider non-cell-autonomous OTX2 activity. Indeed, previous analysis of the *Otx2*^{+AA} mouse model, which results in reduced OTX2 transfer to cortical PV cells, revealed a music preference phenotype linked to anxiolysis [19]. We confirmed anxiolysis-like behavior in *Otx2*^{+AA} mice in the EPM tests (Fig. 3a). Both male and female mice showed increased time in open arms (15.24 ± 2.28 (WT) vs 25.64 ± 3.08 ; $F(1, 49) = 4.1$; $p = 0.048$) and higher number of entries (8.27 ± 1.34 (WT) vs 14.81 ± 0.71 ; $F(1, 48) = 7.86$; $p = 0.0073$), with no change in total distance. However, no significant differences were observed for the LDB test (Fig. 3b).

The observed changes in critical period timing of the *Otx2*^{+AA} mouse model were hypothesized to be due to altered distribution of CSF-borne OTX2 into mPFC PV cells, resulting in accompanying changes in PV and PNN staining and alteration in mPFC circuit recruitment [19]. The ChP not only cleans the CSF from toxic metabolites but also nurtures the brain by secreting into the CSF a large number of trophic factors [34, 35], including OTX2 [11]. To verify if OTX2 secreted by the ChP could regulate anxiety, we took advantage of a conditional mouse line expressing a secreted scFv directed against OTX2 [25]. In this mouse, injection of a cell-permeable Cre recombinase in the lateral ventricles of the brain induces the secretion of the scFv-OTX2 antibody from the ChP, which leads to the neutralization of extracellular OTX2 in the CSF and, in the case of the visual cortex, to the reopening of plasticity in the adult mouse. Through EPM tests, we find that neutralizing ChP-derived OTX2 in the CSF of *scFvOtx2*^{tg/0} mice installs an anxiolysis-like phenotype at P90 (Fig. 3c). These mice showed increased time in open arms (24.60 ± 4.66 (WT) vs 41.69 ± 4.47 ; $t = 2.568$; $p = 0.0130$) and higher number of entries (6.65 ± 0.89 (WT) vs 10.09 ± 1.05 ; $t = 2.328$; $p = 0.0236$), with no change in total distance.

PV expression is reduced in the mPFC of *Otx2*-het mice

The anxiety response is tightly regulated by the mPFC [36], which is mediated in part by PV cells [37]. The above results strongly suggest that non-cell autonomous OTX2 plays a role in mouse anxiety phenotypes. In postnatal mice, *Otx2* is expressed in several extra-cortical structures, including the VTA and ChP [9, 11] but no expression takes place in the cerebral cortex parenchyma [18]. Although not expressed in the cerebral cortex, OTX2 is imported from extra-cortical structures, in particular ChP, by neurons throughout the cortex (primarily PV cells), including primary cortices and limbic structures. Non-cell autonomous OTX2 has been identified in mPFC, hippocampus, and basolateral amygdala [10, 11, 19]. Because of this presence of OTX2 in several structures implicated in the regulation of anxiety-related

behaviors, we tested the expression of different genes in these regions to identify possible altered pathways due to potentially reduced OTX2 level (Fig. 4a). We quantified mRNA levels corresponding to interneuron marker genes (*PV* and *SST*), plasticity genes known to be altered by OTX2 levels (*Gadd45b*, *Arc*, *Nr4a1*), and inflammatory/oxidative stress pathway genes (*Mtnd4* and *Iba1*), given that mood disorders can be related to oxidative stress response [38, 39]. While no significant changes were observed in the amygdala or the hippocampus, *PV* gene expression was significantly reduced in the mPFC of *Otx2-het* mice ($t = 2.293$; $p = 0.04$). This change in *PV* expression was confirmed by the decreases number of cells stained for *PV* in the infralimbic mPFC of *Otx2-het* mice at P90 (Fig. 4b, $t = 2.873$; $p = 0.0263$). Furthermore, the number mature *PV* cells, as defined by PNN intensity, is also compromised; *PV*+*WFA*+ cell number is significantly reduced ($t = 3.180$; $p = 0.0107$), along with overall *WFA* staining intensity per cell ($t = 2.773$; $p = 0.0216$). These results suggest that the observed anxiolysis-like phenotypes are due to changes in infralimbic mPFC *PV* cell populations.

OTX2 secreted by the ChP regulates mouse anxiety

To evaluate the role of ChP-derived OTX2 in the *Otx2-het* mice anxiety levels, we performed a rescue experiment involving ivc injection of AAV serotype 5 encoding *Otx2*. This serotype provides specific infection of the ChP (Fig. 5a) and resulted in ~1.5-fold increase in *Otx2* expression (Fig. 5b, $t = 3.525$; $p = 0.0023$). This overexpression caused increased anxiety in the *Otx2-het* mice in the EPM test (Fig. 5c), resulting in decreased time in the open arms (15.11 ± 3.58 (*Otx2-het*) vs. 6.01 ± 1.54 ; $t = 2.286$; $p = 0.029$) and less entries (19.56 ± 2.02 (*Otx2-het*) vs. 12.78 ± 2.24 ; $t = 2.252$; $p = 0.031$), but with no change in the total distance traveled. Histochemical analysis of *PV* cell maturation (Fig. 5d) showed a trending increase in *PV* cell number ($t = 1.925$; $p = 0.0864$) with a significant increase in PNN+ *PV* cells ($t = 3.173$; $p = 0.0113$) and *WFA* staining intensity ($t = 2.773$; $p = 0.0216$). These experiments suggest that OTX2 expression in the ChP is sufficient to restore a normal anxiety behavior in the *Otx2-het* mouse through accompanying changes in mPFC *PV* cell populations.

DISCUSSION

In this study, we provide evidence for a role of *Otx2* in the regulation of anxious behavior and show that OTX2 secreted from the ChP into the CSF plays a role in this regulation. This does not exclude other extra-cortical sources, in particular the pineal gland, but establishes that the ChP, through the synthesis and secretion of OTX2 is an important anxiety regulator. Anxiety

regulation can be the consequence of modest changes in OTX2 expression and/or secretion. For expression, the AAV5 strategy induces a 50% increase in ChP *Otx2* transcription. For secretion, previous studies using the same neutralization strategy in the CSF showed that a 20% OTX2 decrease in the visual cortex PV cells is sufficient to reopen plasticity in the adult [25]. In the present study, all target structures were not identified, but it can be claimed that an acute decrease of OTX2 en route from the ChP to the brain parenchyma of adult mice (~P90) is enough to decrease anxiety. This result excludes that *Otx2-het* mice anxiolysis-like behavior is purely developmental, as also suggested by the similar reduced anxiety of *Otx2-het* mice between 1 and 4 months of age.

Interestingly, the *Otx2*^{+AA} mutant showed anxiolysis-like behavior in the EPM but not the LDB tests. According to analysis of retina structure and function, this mutant shows OTX2 activity level ~75% of normal, while the *Otx2-het* mouse shows ~50% compared to WT [24]. Furthermore, the *Otx2*^{+AA} mouse shows delays in critical period timing that are not as extended as in the *Otx2-het* mouse [18, 19, 40], suggesting a subtler phenotype is to be expected. Nevertheless, the EPM test appears to be more sensitive than the LDB test for measuring anxiety.

While all non-cell autonomous OTX2 target cells and structures were not investigated, in such complex behaviors, it is likely that several interacting structures are implicated. If so, the presence of OTX2 in the CSF could give the protein access to many candidate target structures functioning in association through the existence of neuronal networks and hub structures [41, 42]. This is apparently the case as non-cell autonomous OTX2 was found in PV cells from the mPFC, ventral hippocampus and amygdala [10, 11]. Interestingly, recent experiments strongly suggest that OTX2 imported in PNN-enwrapped PV cells in the mPFC and in the ventral hippocampus might regulate anxiety [10, 19]. Although the accent here is placed on PV cells, other interneurons might play an OTX2-associated role as suggested in the mPFC where OTX2 is mainly imported by PV+ and calretinin+ interneurons (70% and 20% co-labeling with OTX2, respectively) [19].

The large repertoire of anxiety-related interconnected target structures is also shared by projections from the VTA [4, 5]. Since *Otx2* is expressed in the adult VTA and may regulate the survival of the mDA cells that constitute 65% of the neuronal population in this structure [43], a possible cell-autonomous role of OTX2 on VTA mDA neuron physiology/survival or, alternatively, a non-cell autonomous effect on their hippocampal or cortical targets following its anterograde transport and trans-synaptic passage cannot not be excluded. The experiments demonstrating that the number of mDA neurons is not affected in the mutant at 3 months of

age (the anxiolysis-like phenotype is present already at 1 months and persists at least for 3 more months) is not in favor of the idea that mDA neuron number is at the origin of the phenotype. While we cannot preclude that there were compensatory changes in DA and/or 5HT receptor activity in target regions, we found no change in the amount of DA and DA metabolites in the cortex, hippocampus and striatum, further supporting the view that the mDA “phenotype” is not altered in *Otx2-het* mice. Nor did we find any change in 5HT innervation or the amount of 5HT and of its metabolite 5HIAA which would be expected if the early *Otx2* hypomorphism had shifted the midbrain/hindbrain boundary in a more anterior position [30, 31].

The normal number of mDA neurons and the maintained dopaminergic and serotonergic innervation and metabolism establish that the loss of one *Otx2* allele is not sufficient to significantly modify mDA progenitor numbers, or to significantly decrease mDA neuron survival. However, there are several cases where homeoprotein signaling was found to interact with classical signaling pathways. In the fly wing disk, ENGRAILED co-signals with decapentaplegic for the formation of the anterior cross vein [44], while in the chick optic tectum, it interacts with EphrinA5 and adenosine signaling for growth cone guidance or collapse [45, 46]. A similar interaction was found between PAX6 and netrin signaling in the regulation of oligodendrocyte precursor cell migration [47]. In these cases, secreted homeoprotein facilitates the full activity of classical signaling. Therefore, we cannot preclude that the anxiolysis-like behavior results from modulation of classical neurotransmitter or growth factor activities by non-cell autonomous OTX2.

Maternal separation experiments have established a role for cell-autonomous OTX2 in the VTA [9], independently of the number of mDA neurons or of DA levels and metabolism. A transient decrease in *Otx2* expression between P10 and P20 in mDA neurons of the VTA can trigger a depression-like state in adulthood in male mice following social defeat, suggesting epigenetic alterations independent of cortical plasticity. Our finding that reducing OTX2 in the CSF can reduce anxiety in the adult suggests that the mechanisms involved may differ from those at work in the maternal separation paradigms. Our anxiolysis-like phenotypes across multiple mouse models might be associated with induction of adult cortical plasticity in our conditional models, or with prolonged critical period plasticity in our constitutive models, as previously seen [19]. Indeed, another maternal separation paradigm that results in excessive adult anxiety implicates altered ventral hippocampus PV cell plasticity [10], which is accompanied by increased OTX2 in the ChP and non-cell-autonomous OTX2 in the ventral hippocampus. Nevertheless, we cannot rule out that there is a link between *Otx2* expression in

the VTA during a critical period (from P10 to P20) and the ability of the ChP to direct OTX2 to non-cell-autonomous target structures.

It has been hypothesized that OTX2 signaling orchestrates complex behaviors reflecting the interplay of multiple sequential critical periods and that the consequence of its disruption is a hallmark of psychiatric and intellectual disorders [3, 19]. OTX2 regulates PNN and PV expression levels [16], PNN density is found to be low in the prefrontal cortices of schizophrenia patients [48–50], while weakened PV circuits in the mPFC cause deficits in behavioral aspects of schizophrenia patients [51, 52]. *OTX2* polymorphisms are associated with bipolar disorders [53], altered *OTX2* methylation is predictive of stress-related depression in children [8], and the choroid plexus has been linked with major depressive disorders [54]. These findings suggest the potential therapeutic interest of preserving or restoring PV cell function. Our model supports the hypothesis that *Otx2* loss and gain of function in the adult ChP can regulate anxiety levels in the mouse, although it does not preclude that other models may extend the role of *Otx2* expression, during specific developmental periods, to other pathologies. Manipulating OTX2 levels in the ChP and CSF, coupled with behavioral therapies, may hold promising opportunities for psychiatric disorders.

ACKNOWLEDGEMENTS AND DISCLOSURES

We would like to thank Chantal Dubreuil, Jessica Apulei, and Lucía Jiménez Alonso for technical assistance. Funding was provided by Fondation Bettencourt Schueller, European Research Council Advanced Grant (HOMEOSIGN, ERC-2013-ADG-339379 to A.P.), and Agence Nationale de la Recherche Grant (ANR-11-BLAN-069467 to A.P.). A.P. is cofounder of BrainEver for development of homeoprotein-based therapeutics. The other authors report no biomedical financial interests or potential conflicts of interest.

REFERENCES

1. Acampora D, Mazan S, Lallemand Y, Avantaggiato V, Maury M, Simeone A, et al. Forebrain and midbrain regions are deleted in *Otx2*(-/-) mutants due to a defective anterior neuroectoderm specification during gastrulation. *Development*. 1995;121:3279–3290.
2. Simeone A, Acampora D, Mallamaci A, Stornaiuolo A, D’Apice MR, Nigro V, et al. A vertebrate gene related to orthodenticle contains a homeodomain of the bicoid class and demarcates anterior neuroectoderm in the gastrulating mouse embryo. *EMBO J*. 1993;12:2735–2747.

3. Prochiantz A, Di Nardo AA. Homeoprotein Signaling in the Developing and Adult Nervous System. *Neuron*. 2015;85:911–925.
4. Beier KT, Steinberg EE, Deloach KE, Xie S, Miyamichi K, Schwarz L, et al. Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping. *Cell*. 2015;162:622–634.
5. Morales M, Margolis EB. Ventral tegmental area: Cellular heterogeneity, connectivity and behaviour. *Nat Rev Neurosci*. 2017;18:73–85.
6. Chung CY, Licznernski P, Alavian KN, Simeone A, Lin Z, Martin E, et al. The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons. *Brain*. 2010;133:2022–2031.
7. Di Salvio M, Di Giovannantonio LG, Acampora D, Proserpi R, Omodei D, Prakash N, et al. *Otx2* controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. *Nat Neurosci*. 2010;13:1481–1489.
8. Kaufman J, Wymbs NF, Montalvo-Ortiz JL, Orr C, Albaugh MD, Althoff R, et al. Methylation in OTX2 and related genes, maltreatment, and depression in children. *Neuropsychopharmacology*. 2018;43:2204–2211.
9. Peña CJ, Kronman HG, Walker DM, Cates HM, Bagot RC, Purushothaman I, et al. Early life stress confers lifelong stress susceptibility in mice via ventral tegmental area OTX2. *Science*. 2017;356:1185–1188.
10. Murthy S, Kane GA, Katchur NJ, Lara Mejia PS, Obiofuma G, Buschman TJ, et al. Perineuronal Nets, Inhibitory Interneurons, and Anxiety-Related Ventral Hippocampal Neuronal Oscillations Are Altered by Early Life Adversity. *Biol Psychiatry*. 2019;85:1011–1020.
11. Spatazza J, Lee HHC, Di Nardo AA, Tibaldi L, Joliot A, Hensch TK, et al. Choroid-Plexus-Derived *Otx2* Homeoprotein Constrains Adult Cortical Plasticity. *Cell Rep*. 2013;3:1815–1823.
12. Lee EJ, Kim N, Park JW, Kang KH, Kim W il, Sim NS, et al. Global Analysis of Intercellular Homeodomain Protein Transfer. *Cell Rep*. 2019;28:712-722.e3.
13. Di Nardo AA, Fuchs J, Joshi RL, Moya KL, Prochiantz A. The physiology of homeoprotein transduction. *Physiol Rev*. 2018;98:1943–1982.
14. Prochiantz A, Joliot A. Can transcription factors function as cell-cell signalling molecules? *Nat Rev Mol Cell Biol*. 2003;4:814–819.
15. Di Nardo AA, Joliot A, Prochiantz A. Homeoprotein transduction in neurodevelopment and physiopathology. *Sci Adv*. 2020;6:eabc6374.

16. Beurdeley M, Spatazza J, Lee HHC, Sugiyama S, Bernard C, Di Nardo AA, et al. Otx2 binding to perineuronal nets persistently regulates plasticity in the mature visual cortex. *J Neurosci*. 2012;32:9429–9437.
17. Miyata S, Komatsu Y, Yoshimura Y, Taya C, Kitagawa H. Persistent cortical plasticity by upregulation of chondroitin 6-sulfation. *Nat Neurosci*. 2012;15:414–422.
18. Sugiyama S, Di Nardo AA, Aizawa S, Matsuo I, Volovitch M, Prochiantz A, et al. Experience-Dependent Transfer of Otx2 Homeoprotein into the Visual Cortex Activates Postnatal Plasticity. *Cell*. 2008;134:508–520.
19. Lee HHC, Bernard C, Ye Z, Acampora D, Simeone A, Prochiantz A, et al. Genetic Otx2 mis-localization delays critical period plasticity across brain regions. *Mol Psychiatry*. 2017;22:680–688.
20. Guirado R, Perez-Rando M, Ferragud A, Gutierrez-Castellanos N, Umemori J, Carceller H, et al. A Critical Period for Prefrontal Network Configurations Underlying Psychiatric Disorders and Addiction. *Front Behav Neurosci*. 2020;14:51.
21. Uhlhaas PJ, Roux F, Singer W, Haenschel C, Sireteanu R, Rodriguez E. The development of neural synchrony reflects late maturation and restructuring of functional networks in humans. *Proc Natl Acad Sci U S A*. 2009;106:9866–9871.
22. Sturman DA, Moghaddam B. The neurobiology of adolescence: Changes in brain architecture, functional dynamics, and behavioral tendencies. *Neurosci Biobehav Rev*. 2011;35:1704–1712.
23. Acampora D, Di Giovannantonio LG, Di Salvio M, Mancuso P, Simeone A. Selective inactivation of Otx2 mRNA isoforms reveals isoform-specific requirement for visceral endoderm anteriorization and head morphogenesis and highlights cell diversity in the visceral endoderm. *Mech Dev*. 2009;126:882–897.
24. Bernard C, Kim HT, Torero Ibad R, Lee EJ un., Simonutti M, Picaud S, et al. Graded Otx2 activities demonstrate dose-sensitive eye and retina phenotypes. *Hum Mol Genet*. 2014;23:1742–1753.
25. Bernard C, Vincent C, Testa D, Bertini E, Ribot J, Di Nardo AA, et al. A Mouse Model for Conditional Secretion of Specific Single-Chain Antibodies Provides Genetic Evidence for Regulation of Cortical Plasticity by a Non-cell Autonomous Homeoprotein Transcription Factor. *PLOS Genet*. 2016;12:e1006035.
26. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, et al. Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and α -synuclein-deleted mice. *Exp Neurol*. 2008;210:182–193.

27. Le Pen G, Sonnier L, Hartmann A, Bizot JC, Trovero F, Krebs MO, et al. Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for *Engrailed1*: A new genetic model for Parkinson's disease? *Park Relat Disord*. 2008;14:1063–1071.
28. Nordström U, Beauvais G, Ghosh A, Pulikkaparambil Sasidharan BC, Lundblad M, Fuchs J, et al. Progressive nigrostriatal terminal dysfunction and degeneration in the *engrailed1* heterozygous mouse model of Parkinson's disease. *Neurobiol Dis*. 2015;73:70–82.
29. Beier KT, Gao XJ, Xie S, DeLoach KE, Malenka RC, Luo L. Topological Organization of Ventral Tegmental Area Connectivity Revealed by Viral-Genetic Dissection of Input-Output Relations. *Cell Rep*. 2019;26:159-167.e6.
30. Brodski C, Vogt Weisenhorn DM, Signore M, Sillaber I, Oesterheld M, Broccoli V, et al. Location and size of dopaminergic and serotonergic cell populations are controlled by the position of the midbrain-hindbrain organizer. *J Neurosci*. 2003;23:4199–4207.
31. Millet S, Campbell K, Epstein DJ, Losos K, Harris E, Joyner AL. A role for *Gbx2* in repression of *Otx2* and positioning the mid/hindbrain organizer. *Nature*. 1999;401:161–164.
32. Santangelo AM, Sawiak SJ, Fryer T, Hong Y, Shiba Y, Clarke HF, et al. Insula serotonin 2A receptor binding and gene expression contribute to serotonin transporter polymorphism anxious phenotype in primates. *Proc Natl Acad Sci U S A*. 2019;116:14761–14768.
33. Adhikari A, Topiwala MA, Gordon JA. Synchronized Activity between the Ventral Hippocampus and the Medial Prefrontal Cortex during Anxiety. *Neuron*. 2010;65:257–269.
34. Nedergaard M. Garbage Truck of the Brain. *Science (80-)*. 2013;340:1529–1530.
35. Fame RM, Lehtinen MK. Emergence and Developmental Roles of the Cerebrospinal Fluid System. *Dev Cell*. 2020;52:261–275.
36. Likhtik E, Paz R. Amygdala–prefrontal interactions in (mal)adaptive learning. *Trends Neurosci*. 2015;38:158–166.
37. Courtin J, Chaudun F, Rozeske RR, Karalis N, Gonzalez-Campo C, Wurtz H, et al. Prefrontal parvalbumin interneurons shape neuronal activity to drive fear expression. *Nature*. 2014;505:92–96.
38. Steullet P, Cabungcal JH, Bukhari SA, Ardelt MI, Pantazopoulos H, Hamati F, et al. The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of

- parvalbumin-expressing neuron networks and oxidative stress. *Mol Psychiatry*. 2018;23:2057–2065.
39. Rossetti AC, Paladini MS, Riva MA, Molteni R. Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention. *Pharmacol Ther*. 2020;210:107520.
 40. Apulei J, Kim N, Testa D, Ribot J, Morizet D, Bernard C, et al. Non-cell Autonomous OTX2 Homeoprotein Regulates Visual Cortex Plasticity Through Gadd45b/g. *Cereb Cortex*. 2019;29:2384–2395.
 41. Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. *Nat Rev Neurosci*. 2015;16:317–331.
 42. Lüthi A, Lüscher C. Pathological circuit function underlying addiction and anxiety disorders. *Nat Neurosci*. 2014;17:1635–1643.
 43. Di Salvio M, Di Giovannantonio LG, Omodei D, Acampora D, Simeone A. Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. *Int J Dev Biol*. 2010;54:939–945.
 44. Layalle S, Volovitch M, Mugat B, Bonneaud N, Parmentier ML, Prochiantz A, et al. Engrailed homeoprotein acts as a signaling molecule in the developing fly. *Development*. 2011;138:2315–2323.
 45. Stettler O, Joshi RL, Wizenmann A, Reingruber J, Holcman D, Bouillot C, et al. Engrailed homeoprotein recruits the adenosine A1 receptor to potentiate ephrin A5 function in retinal growth cones. *Development*. 2012;139:215–224.
 46. Wizenmann A, Brunet I, Lam JSY, Sonnier L, Beurdeley M, Zarbalis K, et al. Extracellular Engrailed Participates in the Topographic Guidance of Retinal Axons In Vivo. *Neuron*. 2009;64:355–366.
 47. di Lullo E, Haton C, le Poupon C, Volovitch M, Joliot A, Thomas JL, et al. Paracrine Pax6 activity regulates oligodendrocyte precursor cell migration in the chick embryonic neural tube. *Development*. 2011;138:4991–5001.
 48. Alcaide J, Guirado R, Crespo C, Blasco-Ibáñez JM, Varea E, Sanjuan J, et al. Alterations of perineuronal nets in the dorsolateral prefrontal cortex of neuropsychiatric patients. *Int J Bipolar Disord*. 2019;7:24.
 49. Mauney SA, Athanas KM, Pantazopoulos H, Shaskan N, Passeri E, Berretta S, et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. *Biol Psychiatry*. 2013;74:427–435.
 50. Enwright JF, Sanapala S, Foglio A, Berry R, Fish KN, Lewis DA. Reduced labeling of

- parvalbumin neurons and perineuronal nets in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Neuropsychopharmacology*. 2016;41:2206–2214.
51. Glausier JR, Fish KN, Lewis DA. Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects. *Mol Psychiatry*. 2014;19:30–36.
 52. Brown JA, Ramikie TS, Schmidt MJ, Báldi R, Garbett K, Everheart MG, et al. Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes. *Mol Psychiatry*. 2015;20:1499–1507.
 53. Sabunciyan S, Yolken R, Ragan CM, Potash JB, Nimgaonkar VL, Dickerson F, et al. Polymorphisms in the homeobox gene OTX2 may be a risk factor for bipolar disorder. *Am J Med Genet Part B Neuropsychiatr Genet*. 2007;144:1083–1086.
 54. Turner CA, Thompson RC, Bunney WE, Schatzberg AF, Barchas JD, Myers RM, et al. Altered choroid plexus gene expression in major depressive disorder. *Front Hum Neurosci*. 2014;8:238.

FIGURE LEGENDS

Fig. 1 Sex indifferent anxiolysis-like behavior in *Otx2-het* mice.

a Light-dark box test of adult mice (P90 to P120) during a 10 min period (WT females n=15; WT males n=16; *Otx2-het* females n=16; *Otx2-het* males n=14). **b** Elevated plus maze test during a 10 min period (WT females n=15; WT males n=15; *Otx2-het* females n=15; *Otx2-het* males n=14). **c** Elevated plus maze performed in normal (50 lux) or dark (0 lux) conditions (WT light n=13; WT dark n=12; *Otx2-het* light n=11; *Otx2-het* dark n=12). **d** Elevated plus maze test at different ages (WT P30 n=44; WT P60 n=39; WT P90 n=16; WT P120 n=33; *Otx2-het* P30 n=32; *Otx2-het* P60, n=35; *Otx2-het* P90 n=22; *Otx2-het* P120 n=31). All values: mean \pm SEM; two-way ANOVA, post hoc Tukey test; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Fig. 2 Dopaminergic and serotonergic markers are not disturbed in the *Otx2-het* mice.

a Representative images and quantification of tyrosine hydroxylase (TH) immunostaining in the ventral tegmental area (VTA) of *Otx2-het* (n=4) and WT (n=5) mice at ~P90 (scale bar: 50 μ m). **b** Quantification of metabolites related to the dopaminergic and serotonergic systems in extracts from anterior cortex (Cx Ant) and posterior cortex (Cx Post), striatum (Str), and hippocampus (Hipp) of ~P90 mice (WT n=5; *Otx2-het* n=7). DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; 5HT, 5-hydroxytryptamine; 5HIAA, 5-hydroxyindoleacetic acid. **c** Representative images and quantification of immunostaining of fibers for dopamine transporter (DAT), TH, and tryptophan hydroxylase 2 (TPH2) in the basolateral amygdala (BLA) of *Otx2-het* (n=7) and WT (n=6) mice (scale bar: 250 μ m). All values: mean \pm SEM; *t*-test.

Fig. 3 Anxiolysis-like behavior in non-cell autonomous OTX2 knock-down mouse models.

a Elevated plus maze test of *Otx2^{+AA}* mice at P90 during a 10 min period (WT females n=9; WT males n=12; *Otx2^{+AA}* females n=12; *Otx2^{+AA}* males n=20). **b** Light-dark box test of *Otx2^{+AA}* mice at P90 during a 10 min period (WT females n=15; WT males n=16; *Otx2^{+AA}* females n=16; *Otx2^{+AA}* males n=14). **c** Elevated plus maze test of *scFvOtx2^{tg0}* mice at ~P100, 15 days after intracerebroventricular (icv) injection of vehicle (Veh, n=23) or Cre recombinase (Cre-TAT, n=34). All values: mean \pm SEM; two-way ANOVA, post hoc Tukey test in **a** and **b**; *t*-test in **c**; * $p < 0.05$, ** $p < 0.01$.

Fig. 4 Downregulated parvalbumin (PV) expression in the medial prefrontal cortex (mPFC) of *Otx2-het* mice.

a Analysis of mRNA levels of genes associated with interneurons (*PV*; *SST*, somatostatin), plasticity (*Gadd45b*, Growth arrest and DNA-damage-inducible beta; *Arc*, activity-regulated cytoskeleton-associated protein; *Nr4a1*, nuclear receptor subfamily 4 group A member 1), and metabolism/inflammation (*Mtnd4*, mitochondrial NADH-ubiquinone oxidoreductase chain 4; *Iba1*, ionized calcium-binding adapter molecule 1) in extracts from the mPFC, hippocampus, and amygdala of WT (n=8) and *Otx2-het* (n=6) mice at ~P90. Data are normalized to *Ywhaz* levels of WT mice. **b** Representative images and quantification of PV and *Wisteria floribunda* agglutinin (WFA) staining in the infralimbic mPFC of WT (n=6) and *Otx2-het* (n=6) mice at P90 (scale bar: 50 μ m). All values: mean \pm SEM; *t*-test; **p* < 0.05.

Fig. 5 Overexpression of OTX2 in the choroid plexus *Otx2-het* mice increases anxiety.

a Image of mCherry staining in a coronal section of a P100 *Otx2-het* mouse, 3 weeks after intracerebroventricular (icv) injection of AAV5(CMV)HAOtx2-2A-mCherry virus, which specifically infects the choroid plexus (scale bar: 100 μ m). **b** Analysis of *Otx2* mRNA levels (normalized to *Ywhaz*) in choroid plexus extracts 3 weeks after icv virus injection (AAV5-control n=9; AAV5-Otx2 n=12). **c** Elevated plus maze test of *Otx2-het* mice during a 10 min period, 4 weeks after icv injection of AAV5-control (n=19) or AAV5-Otx2 (n=17). **d** Quantification of parvalbumin (PV) and *Wisteria floribunda* agglutinin (WFA) staining in the infralimbic medial prefrontal cortex (mPFC) of *Otx2-het* mice, 4 weeks after AAV5-control (n=6) or AAV5-Otx2 (n=5) icv injection. All values: mean \pm SEM; *t*-test; **p* < 0.05, ***p* < 0.01.

Supplementary Fig. 1 Behavioral analysis of adult male and female *Otx2-het* mice .

a Rotarod test with a progressively accelerating rotating rod from 2 to 40 rpm during 5 min trial (WT females n=16; WT males n=18; *Otx2-het* females n=10; *Otx2-het* males n=14). **b** Forced swim test during a 6 min period in a small pool (WT females n=16; WT males n=17; *Otx2-het* females n=10; *Otx2-het* males n=14). **c** Tail suspension test during a 6 min period (WT females n=16; WT males n=17; *Otx2-het* females n=10; *Otx2-het* males n=15). **d** Y-maze test during a 10 min period (WT females n=16; WT males n=17; *Otx2-het* females n=10; *Otx2-het* males n=15). **e, f** Prepulse inhibition (PPI) test performed in a startle chamber to measure startle response amplitude **f** and %PPI **e** at various pulse intensities (WT females

n=16; WT males n=18; *Otx2-het* females n=10; *Otx2-het* males n=14). All values: mean \pm SEM; two-way ANOVA, post hoc Tukey test; *p < 0.05, **p < 0.01.









